Amgen eyes potential acquisitions
Executive Summary
Amgen's consolidation of Immunex gives the company confidence that it could pursue other large agreements, CEO Sharer said Feb. 25, but "that doesn't mean we're just going to [do] it for the heck of it." While "acquisitions are something that we don't expect," Sharer says, "obviously, given that prices are much lower right now, we're looking harder." The CEO outlined Amgen's criteria for a takeover prospect, which include an ability to drive top-line growth and a fit with Amgen's culture...
You may also be interested in...
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Timely Acquisition Keeps Germany's Dermapharm Growing
With its Branded Pharmaceuticals division negatively impacted by the end of the COVID-19 pandemic, the timely acquisition of supplements firm Arkopharma ensured Dermapharm recorded double-digit sales growth in 2023.
Executives On The Move: Changes At The Top At Enzolytics, Dyne Therapeutics And Seres Therapeutics
Recent moves in the industry include new chief financial officers at LENZ Therapeutics and Botanix Pharmaceuticals, plus new chief medical officers at Vigil Neuroscience and Voyager Therapeutics.